View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 20, 2019

Baring Private Equity Asia signs agreement to buy Lumenis

Baring Private Equity Asia’s (BPEA) affiliated private equity funds have signed an agreement to buy Lumenis, a provider of speciality energy-based medical devices.

Baring Private Equity Asia ’s (BPEA) affiliated private equity funds have signed an agreement to buy Lumenis, a provider of speciality energy-based medical devices.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The deal takes enterprise value of Lumenis to more than $1bn.

Lumenis provides minimally invasive clinical solutions for aesthetic, surgical and ophthalmology specialities.

It has been operating in the field for more than five decades and has around 1,500 employees across its global operations.

It has a presence in more than 100 countries, with Asia Pacific region being its largest market.

Lumenis CEO Tzipi Ozer-Armon said: “BPEA’s investment is a tremendous vote of confidence in Lumenis and in the achievements of our entire global organisation. In recent years, we have developed and introduced multiple groundbreaking technological solutions that have redefined our industry and opened entirely new market segments.

“I would like to thank the entire Lumenis team, I am truly proud of all we have accomplished and honoured to lead a company on the cutting edge of healthcare innovation, committed to improving the lives of people across the world.

“We look forward to partnering with the team at BPEA to continue developing and delivering to the world better technology for better patient care.”

BPEA managing director Yan Jiao said: “Lumenis has built a market-leading position by creating some of the most innovative technologies in the industry. It is a clear leader worldwide, especially in Asia which recently emerged as the largest market for medical and aesthetic treatments.

“We look forward to working with the CEO and management team to support their global growth aspirations.”

Subject to the customary regulatory approvals, the deal is expected to complete in early 2020.

Baring Private Equity Asia has a total committed capital of more than $18bn.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network